Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
about
Alectinib for treatment of ALK-positive non-small-cell lung cancer.Metabolites of alectinib in human: their identification and pharmacological activity.Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
P2860
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Absorption, distribution, meta ...... nce study in healthy subjects.
@en
Absorption, distribution, meta ...... nce study in healthy subjects.
@nl
type
label
Absorption, distribution, meta ...... nce study in healthy subjects.
@en
Absorption, distribution, meta ...... nce study in healthy subjects.
@nl
prefLabel
Absorption, distribution, meta ...... nce study in healthy subjects.
@en
Absorption, distribution, meta ...... nce study in healthy subjects.
@nl
P2093
P2860
P1433
P1476
Absorption, distribution, meta ...... nce study in healthy subjects.
@en
P2093
Alex Phipps
David J Moore
Dieter Muri
Elena Guerini
Hisakazu Katsuki
Katja Heinig
Katrijn Bogman
Keith Nieforth
Kosuke Kawashima
P2860
P304
P356
10.1080/00498254.2016.1179821
P407
P577
2016-05-16T00:00:00Z